Add BrightSurf on Google Email

Antibodies in breast milk provide protection against common GI virus

A study by researchers at the University of Rochester Medical Center found that high levels of specific antibodies in breast milk provide protection against rotavirus, a common gastrointestinal disease. The findings highlight the importance of optimized breastfeeding practices to improve infant health globally.

SourceUniversity of Rochester Medical Center·JournalJournal of Clinical Investigation·TypeData/statistical analysis·DateOct 1, 2024

Amsterdam UMC led research sets a step forward in the battle against MRSA

A recent study published in Cell Reports Medicine has discovered an important immune component that offers protection against MRSA infection. The researchers found that IgM antibodies are required for clearance of S. aureus during an infection, suggesting a new direction for future vaccine strategies and therapies.

SourceAmsterdam University Medical Center·JournalCell Reports Medicine·TypeExperimental study·DateSep 17, 2024

Autoantibodies behind lifelong risk of viral infections

A new study reveals that about two percent of the population develop autoantibodies against type 1 interferons, making them more susceptible to severe viral infections. The autoantibodies remain detectable in the blood for life and are associated with a compromised type 1 interferon system.

SourceUniversity of Zurich·JournalJournal of Experimental Medicine·TypeData/statistical analysis·DateJul 17, 2024

The recipe for a great antibody

Researchers at Lund University developed a hybrid antibody that significantly improves immune function despite weaker binding to antigens. The new antibody's longer stem enhances mobility and signaling capacity, leading to better protection against SARS-CoV-2 and streptococcal bacteria.

SourceLund University·JournalNature Communications·TypeExperimental study·DateJun 25, 2024

Could auto-antibodies be linked to severe COVID-19?

Researchers found auto-antibodies against type I interferons in severe and critical COVID-19 patients, compromising their immune response. This discovery highlights the importance of detecting these auto-antibodies in regular health checkups to better prepare for viral infections.

SourceChiba University·JournalJournal of Clinical Immunology·TypeObservational study·DateJun 19, 2024

A new antibody capture method reveals G-quadruplex landscape and its regulation

Researchers developed an improved method for G4 landscape determination, revealing that sequence property-specific constraints in the nuclear environment mitigate G4 formation. The technique, AbC G4-ChIP, captures G4s efficiently without bias, showing that depletion of a repeat-binding protein enhances net G4 capture at specific sites.

SourceImpact Journals LLC·JournalOncotarget·TypeObservational study·DateMar 18, 2024

Vac to the future

A competition among researchers predicted B. pertussis vaccine responses based on a simple correlation between calendar age and antibody responses. The result highlights the need for further research to understand variability in vaccination outcomes.

SourceLa Jolla Institute for Immunology·JournalCell Reports Methods·TypeData/statistical analysis·DateMar 14, 2024

Gut bacteria important for overcoming milk allergy

Researchers at RIKEN found that gut bacteria, particularly Bifidobacterium, are associated with higher chances of successful milk-allergy treatment. However, only 7 out of 28 children who underwent oral immunotherapy passed the food challenge after a two-week milk avoidance period.

SourceRIKEN·JournalAllergology International·DateMar 14, 2024

Prior zika infection increases risk of subsequent severe dengue and hospitalization, study concludes

A Brazilian study found that prior zika infection significantly increases the risk of developing severe dengue and being hospitalized. The study analyzed samples from over 1,000 laboratory-confirmed dengue patients and identified a higher viral load and inflammatory cytokine levels in those with prior zika infections.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalPLOS Neglected Tropical Diseases·DateFeb 6, 2024

New vaccine design uses immunity against influenza to offer faster protection against emerging pathogens

A new vaccine design has been developed by a UC Riverside-led research team, which uses preexisting immunity to the influenza virus to help kickstart the production of antibodies against SARS-CoV-2. The vaccine aims to speed up the immune response and provide better protection for people who still lack immunity to the coronavirus.

SourceUniversity of California - Riverside·JournalJournal of Virology·TypeExperimental study·DateJan 17, 2024

B cell response after influenza vaccine in young and older adults

Researchers found a quantitative difference in B cell response following vaccination between young and older adults, with younger adults mounting a stronger clonal response and older adults having more activated B cells. This study provides insights into the age-related differences in B cell vaccine response and may lead to the develop...

SourceImpact Journals LLC·JournalAging-US·TypeObservational study·DateOct 10, 2023

Rapid acting, oral vaccines are coming soon

Researchers have developed a new vaccination method that induces the production of antibodies in mucus, which can disable viruses. This approach has shown promising results in monkeys, suggesting that oral vaccines against SARS-CoV-2 may be more effective and popular than traditional subcutaneous vaccinations.

SourceOxford University Press USA·JournalBiology Methods and Protocols·TypeExperimental study·DateSep 13, 2023

3D genome analysis reveals secrets to antibody diversity

Researchers at the Babraham Institute have discovered that the 3D organisation of DNA in B cells allows for genes far away from each other to come together during antibody generation. This finding has implications for understanding why antibody diversity declines with age and suggests potential interventions.

SourceBabraham Institute·JournalCell Reports·TypeExperimental study·DateSep 7, 2023

Research uncovers possible monoclonal antibody treatment for Lassa fever

Researchers at the University of Texas Medical Branch have identified a possible treatment for Lassa fever, a highly infectious and often fatal disease. A new monoclonal antibody cocktail, Arevirumab-3, was shown to successfully treat cynomolgus monkeys infected with the virus in advanced stages.

SourceUniversity of Texas Medical Branch at Galveston·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateAug 24, 2023

Three doses of COVID-19 vaccine leads to catch-up antibody responses among the particularly vulnerable

A study from the University of Gothenburg found that even vulnerable people with compromised immune systems achieved good antibody levels after three doses of COVID-19 mRNA vaccine. This is particularly significant for those at risk of severe Covid-19, as they showed catch-up antibody responses and high levels of hybrid immunity.

SourceUniversity of Gothenburg·JournalInfectious Diseases·TypeObservational study·DateAug 1, 2023

Study uncovers how B cells react to skin cancer

A new study reveals that antibody-producing B cells in patients with melanoma may be defective, leading to ineffective responses against the disease. The research finds that active B cells accumulate at the edge of tumors and gather in small groups, carrying specific antibody features that react with T cells and other immune cells.

SourceKing's College London·JournalNature Communications·TypeExperimental study·DateJun 8, 2023

ASCO: HER2-targeted antibody drug conjugate shows strong anti-tumor activity and durable responses across multiple tumor types

The study found an objective response rate of 61.3% with a median duration of response of 22.1 months in patients with high HER2 expression. The treatment showed promise in a significant unmet area of clinical need, providing a new option for patients with hard-to-treat HER2-positive cancers.

SourceUniversity of Texas M. D. Anderson Cancer Center·TypeRandomized controlled/clinical trial·DateJun 5, 2023